SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

UBS Maintains Neutral on Amedisys, Raises Price Target to $154

UBS maintains Amedisys (NASDAQ:AMED) with a Neutral and raises the price target from $144 to $154.

Benzinga · -

UBS maintains Amedisys (NASDAQ:AMED) with a Neutral and raises the price target from $144 to $154.